Table 2 Somatic characteristics in our sample of participants with schizophrenia
Characteristics | Total sample (n = 187) | Males (n = 108) | Females (n = 79) |
|---|---|---|---|
Somatic features | |||
 Body Mass Index[kg/m2], mean (SD) | 28.5 (6.1) | 28.1 (5.8) | 29.0 (6.5) |
 Systolic blood pressure [mmHg], mean (SD) | 126.1 (15.7) | 130.2 (16.3) | 120.8 (13.3) |
 Diastolic blood pressure [mmHg], mean (SD) | 79.8 (10.6) | 81.7 (11.0) | 77.4 (9.6) |
Blood indices | |||
 suPAR [ng/ml], mean (SD) | 1.8 (0.6) | 1.7 (0.5) | 2.0 (0.6) |
 hsCRP [mg/L], mean (SD) | 2.2 (1,5) | 2.2 (1.4) | 2,3 (1.5) |
 HDL cholesterol [mmol/L], mean (SD) | 1.2 (0.4) | 1.1 (0.3) | 1.4 (0.4) |
 LDL cholesterol [mmol/L], mean, (SD) | 3.0 (1.1) | 3.0 (1.1) | 3.0 (1.1) |
 Triglycerides [mmol/L], median (IQR) | 1.4 (0.9–2.2) | 1.5 (1.0–2.6) | 1.3 (0.9–1.9) |
 Fasting glucose[mmol/L], mean (SD) | 5.3 (0.9) | 5.3 (0.8) | 5.2 (1.1) |
Atherogenic index of plasma, mean (SD) | 0.1 (0.3) | 0.2 (0.3) | 0.0 (0.3) |
Comorbid diseases | |||
 Cardiovascular disease, n (%) | 21 (11.9) | 13 (13.0) | 8 (10.4) |
 Diabetes type II, n (%) | 7 (4.0) | 3 (3.0) | 4 (5.2) |
 Infectious and autoimmune diseases, n (%) | 12 (6.8) | 7 (7.0) | 5 (6.5) |
Antipsychotic medication | |||
 Antipsychotic medication [DDD], mean (SD) | 1.3 (1.0) | 1.3 (1.0) | 1.3 (1.0) |
 aAntipsychotic metabolic risk | |||
 No antipsychotic medication, n (%) | 20 (10.7) | 12 (11.1) | 8 (10.1) |
 Low level, n (%) | 27 (14.4) | 15 (13.9) | 12 (15.2) |
 Moderate level, n (%) | 76 (40.6) | 39 (36.1) | 37 (46.8) |
 High level, n (%) | 64 (34.2) | 42 (38.9) | 22 (27.8) |